A QS21 + CpG-Adjuvanted Trivalent HSV-2 Vaccine and Trivalent HSV-2 mRNA Vaccine Induce a Strong Immune Response, Protect Against HSV-2 Infection, and Cross-Protect Against HSV-1 Infection in Mice
These findings provide valuable insights for the continued development of effective HSV vaccines and suggest promising strategies for preventing both HSV-2 and HSV-1 infection.
Authors
- Cunbao Liu (ORCID: https://orcid.org/0000-0002-2101-2612)
- Jingping Hu (ORCID: https://orcid.org/0000-0001-5548-1241)
- Haihao Zhang
- Han Cao (ORCID: https://orcid.org/0000-0003-3612-6169)
- Ning Luan (ORCID: https://orcid.org/0000-0001-8559-7464)
- Dandan Gao (ORCID: https://orcid.org/0000-0002-2035-8769)
- Xiaolong Zhang (ORCID: https://orcid.org/0000-0002-9423-1461)
- Yang Li
- Yu‐Feng Yao
- Bingyan Liang (ORCID: https://orcid.org/0009-0001-4936-3107)
- Zhentao Lei
- Jishuai Cheng (ORCID: https://orcid.org/0000-0003-0769-858X)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Kunming Medical University (CN)
Publication Details
- Journal
- Vaccines
- Published
- 2025-05-06
- DOI
- https://doi.org/10.3390/vaccines13050497
- Citations
- 4
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China